Results 201 to 210 of about 26,534 (253)
Advanced Healthcare Materials, EarlyView.ABSTRACT Magnetogenetic deep brain stimulation (MG‐DBS) represents a wireless neuromodulation that has demonstrated long‐lasting behavioral benefits in Parkinson's disease models. However, the circuit‐level mechanisms underlying these therapeutic effects have remained uncharacterized due to limitations of conventional neural interfaces.
Jakyoung Lee +10 more
wiley +1 more source
Treatment Satisfaction with Tenapanor: Real-World Survey of Patients with End-Stage Renal Disease and Hyperphosphatemia. [PDF]
Patient Prefer AdherenceKendrick JB +3 more
europepmc +1 more source
Advanced Healthcare Materials, EarlyView.Sweetosomes, a new class of fucose‐decorated liposomes, are developed via a one‐step microfluidic process without surface chemistry. This study elucidates their main caveolae‐mediated entry and distinct endosomal trafficking. These nanostructures demonstrate superior endosomal escape, organelle acidity modulation, and prolonged plasma persistence ...
Mattia Tiboni +13 more
wiley +1 more source
Comprehensive Toxicological Evaluation of 3D-Printed Hydroxyapatite (3DPHA) for Bone Grafting Applications. [PDF]
Int J Mol SciThammarakcharoen F +5 more
europepmc +1 more source
Wet Granulation as a Solidification Strategy for Converting Aqueous Nanosuspensions into Solid Dosage Forms. [PDF]
PharmaceuticsRagucci E +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hyperphosphatemia and phosphate binders
American Journal of Health-System Pharmacy, 2005The pathophysiology of hyperphosphatemia associated with end-stage renal disease and treatment with phosphate binders are discussed.Phosphorus is an essential element necessary for the normal function of the human body, required for skeletal construction and synthesis of DNA, proteins, and adenosine triphosphate.
Jason J, Schucker, Kristina E, Ward
openaire +2 more sources
The safety of phosphate binders
Expert Opinion on Drug Safety, 2006Disturbances of mineral metabolism occur during the early stages of chronic kidney disease. As renal function worsens, excess dietary phosphorus accumulates and blood levels increase, that can be clearly seen when the glomerular filtration rate has fallen below 30 ml/min/1.73 m2.
Jaume, Almirall +3 more
openaire +2 more sources
Lanthanum: A Safe Phosphate Binder
Seminars in Dialysis, 2006ABSTRACTAccumulation of inorganic phosphate due to renal functional impairment contributes to the increased cardiovascular mortality observed in dialysis patients. Phosphate plays a causative role in the development of vascular calcification in renal failure; treatment with calcium‐based phosphate binders and vitamin D can further increase the Ca × PO4
Veerle P, Persy +4 more
openaire +2 more sources
The Phosphate Binder Equivalent Dose
Seminars in Dialysis, 2011AbstractPhosphate binders include calcium acetate or carbonate, sevelamer hydrochloride or carbonate, magnesium and lanthanum carbonate, and aluminum carbonate or hydroxide. Their relative phosphate‐binding capacity has been assessed in human, in vivo studies that have measured phosphate recovery from stool and/or changes in urinary phosphate excretion
John T, Daugirdas +3 more
openaire +2 more sources
Reasons for Phosphate Binder Discontinuation Vary by Binder Type
Journal of Renal Nutrition, 2014Nonadherence to phosphate binder regimen is common among end-stage renal disease patients and contributes to elevated phosphorus levels. Pill burden, side effects, complex regimens, and cost all contribute to nonadherence. We retrospectively analyzed reasons for discontinuation in hemodialysis patients receiving treatment at a large U.S.
Steven, Wang +5 more
openaire +2 more sources